Table 1 Key characteristics of the included trials
Study | Trial name | Interventions vs. placebo | Trial duration (double-blind phase) | Number of randomized patients | Migraine type | MMD at baseline | Mean age (years) | % Male |
|---|---|---|---|---|---|---|---|---|
Silberstein 2004 [30] | MIGR-001 | Topiramate 50/100/200 mg | 26 weeks | 487 | EM | 6.4 | 40.3 | 11.3 |
Brandes 2004 [6] | MIGR-002 | Topiramate 50/100/200 mg | 26 weeks | 483 | EM | 6.5 | 38.8 | 13.2 |
Diener 2004 [31] | MIGR-003 | Topiramate 100/200 mg Propranolol 160 mg | 26 weeks | 575 | EM | 6.0 | 40.9 | 20.2 |
Mei 2004 [32] | - | Topiramate 100 mg | 16 weeks | 50 | EM | 5.5 | 39.2 | 45.8 |
Silberstein 2006 [33] | - | Topiramate 200 mg | 20 weeks | 213 | EM | 4.9 | 40.5 | 14.2 |
Diener 2007 [34] | TOPMAT-MIG-201 | Topiramate 50–200 mg | 16 weeks | 59 | CM | 15.9 | 46.2 | 25.4 |
Silberstein 2007 [35] + Silberstein 2009 [36] | Topiramate Chronic Migraine | Topiramate 100 mg | 16 weeks | 358 | CM | 15.2 | 38.2 | 14.7 |
Lipton 2011 [37] | INTREPID | Topiramate 100 mg | 26 weeks | 385 | (HF)EM | 11.7 | 40.3 | 10.9 |